What is Syntaxin?
Syntaxin.com represents a unique intersection of biological intelligence and digital code, positioning itself as a next-generation platform for coding assistance, compilers, or DevOps tools. The name itself, combining 'syntax' with the concept of integration, signals precision and innovation. This domain is particularly valuable for businesses operating at the forefront of Deep Tech and AI, offering scientific authority and appealing to clients in biotech research labs and pharmaceutical startups. The company's focus on bridging life sciences and technology suggests a strong potential for disruption in both fields.
How much funding has Syntaxin raised?
Syntaxin has raised a total of $71.4M across 3 funding rounds:
Series A
$10.4M
Series B
$32M
Series C
$29M
Series A (2005): $10.4M with participation from Abingworth
Series B (2007): $32M led by Abingworth, Johnson & Johnson, and SrOne
Series C (2010): $29M supported by Life Sciences Partners, Johnson & Johnson, SrOne, and Abingworth
Key Investors in Syntaxin
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that provides capital and expertise to transform cutting-edge science into novel medicines. They focus on seed, early-stage, and development-stage therapeutic investments.
Johnson & Johnson
Johnson & Johnson is a global healthcare company with a broad range of products in baby care, feminine hygiene, and wound care, among others. Their investment suggests a strategic interest in the intersection of technology and life sciences.
SrOne
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, often leading financings and providing strategic support.
What's next for Syntaxin?
With a substantial enterprise-level funding injection, Syntaxin is strategically positioned to accelerate its development and market penetration. The recent major strategic investment signals strong investor confidence in the company's vision and technological capabilities. This capital infusion will likely fuel further research and development, enhance its platform offerings, and expand its operational footprint. The company's trajectory suggests a focus on solidifying its position as a leader in the convergence of biological intelligence and digital code, potentially exploring new applications and partnerships within the Deep Tech and AI ecosystems.
See full Syntaxin company page
